IMPROBABLE
24.7.2024 14:01:33 CEST | Business Wire | Press release
Highlights
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240724891104/en/
-
Profitability achieved in 2023
- Improbable submitted its filing to Companies House today. In 2023 the company achieved profitability, validating its technology and business.
- Excluding one-time items, revenue increased by 37%, to a total of £66 million.
- Improbable achieved profitability for the first time, recording £11 million in profit.
- The company ended 2023 with a strong cash position of £185 million, driven by successful exits of its initial ventures.
- The strategic focus on the metaverse early 2022 resulted in rightsizing of the company, generating increasing revenue and optimizing operations.
-
Technological edge and market position
- A decade of investment and experience in high-performance distributed systems has positioned Improbable at the forefront of addressing scale in traditional cloud computing.
- Additionally, having deployed its technologies throughout dozens of commercial applications, Improbable is leveraging this experience towards the development of emerging technologies for the metaverse, blockchain and AI.
- The MSquared Platform now has many external content developers in early access mode and tens of metaverse projects are being regularly tested with consumers.
-
Successful shift to Venture Building in 2023
- Improbable announced its transition to a venture builder model in Q3 2023, and triggered its first important exit with the sale of its games services business, MPG, at the end of the year.
- The approach focuses on building ventures in cutting-edge sectors like AI, blockchain, and the metaverse, investing in both Infrastructure Ventures that serve as platforms for businesses and B2B or Consumer Application Ventures.
-
Support for ventures for a fast start
- The company will deploy capital along with a broad set of support services, supporting founders with fundraising, strategic advice and simplified operations.
-
A hands-on approach for 2024-2025
- Improbable aims to launch multiple start-ups annually, creating commercially successful businesses, and participating into a high value portfolio.
- The company maintains equity in a valuable portfolio, contributing ideas and resources, and offering more operational involvement than typical funds or investors.
Herman Narula, Founder and Chief Executive Officer of Improbable declared: "A decade ago, we embarked on the challenging yet immensely rewarding journey of focusing on distributed systems for virtual worlds. Over this period, we have honed our expertise in bringing complex technology products to market, seeded and grown businesses, and developed proprietary technology with significant barriers to entry.
Two years ago, we doubled down on our commitment to the metaverse. In 2023, we recorded revenues of £66 million and achieved a total profit of £11 million, driven by growth, cost discipline, and divestment of high-value assets. We’ve uniquely demonstrated the ability to pursue distinct, real businesses simultaneously. Venture building has proven to be the optimal model for both Improbable and the metaverse, as experimenting with various use cases is key to achieving adoption.
Through strategic investments in both large partnerships and start-ups, we continue to advance the case for the metaverse. Our ambition is to shape the future, and our experience provides us with unique insights to do so. I extend my heartfelt thanks to our leadership team, especially our CFO, Dan Odell, for their unwavering dedication in propelling Improbable to its current place of strength."
Dan Odell, Chief Financial Officer: “Entering 2024, we have significantly improved our cost structure, and can count on a strong capital position further supported by the successful exits of our first ventures. Improbable has laid the foundation for executing on its Venture Builder strategy. The portfolio of ventures as we enter 2024 is exciting and I trust in the future success of the business.”
Peter Lipka, Chief Operating Officer: “We believe that there are significant unaddressed opportunities in the AI, web3 and metaverse sectors. We aim to identify founders that we can help accelerate by unlocking the capital they need, and providing a foundation for them to operate on. Our goal is for our venture builder model to be the best place to start a business in these sectors.”
Rob Whitehead, Chief Product Officer: “We are proud to continue hosting the highest density virtual events in the world. After primarily using this technology internally, we are thrilled to start opening our platform to external developers later this year, starting with Yuga Lab's Otherside Developer Kit (ODK). Our next steps involve enhancing this toolset, further developing interoperability on our network, advancing blockchain technology for metaverse applications, and exploring the transformative impact of Generative AI.”
Improbable is a start-up that has been at the forefront of building virtual worlds for over a decade.
We believe that the metaverse is an opportunity for communities, companies and brands to have a positive social and economic impact in the real world. Today, we are initiating new technologies, models and partnerships to venture further into new worlds.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724891104/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
